» Articles » PMID: 14514341

Prevalence and Natural History of Adrenal Incidentalomas

Overview
Specialty Endocrinology
Date 2003 Sep 30
PMID 14514341
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

Clinically silent adrenal masses discovered by imaging studies performed for unrelated reasons, i.e. adrenal incidentalomas, have become a rather common finding in clinical practice. However, only limited studies of incidence, prevalence, and natural history of adrenal incidentalomas are available. A comprehensive review of the literature shows the prevalence of adrenal incidentalomas to be 2.3% at autopsy and 0.5-2% at abdominal computed tomography scan. Most lesions are adrenocortical adenomas at histology, whereas the prevalence of adrenocortical carcinomas is relatively low. The risk of malignancy over time for masses defined as benign at diagnosis is estimated at about 1/1000, even though 5-25% of masses increase in size during follow-up. Hyperfunction develops in about 1.7% of cases and the risk is higher in patients with lesions larger than 3 cm. Cortisol hypersecretion is the most likely disorder that may ensue, and it remains subclinical in about two-thirds of cases. The lack of controlled studies precludes making specific management recommendations. Large perspective controlled studies to define the epidemiology, natural history, and possible associated morbidity of adrenal incidentalomas and their impact on the quality of life of patients are needed.

Citing Articles

Evaluation of adrenal tumors and analysis of the metabolic profile of patients with incidentaloma.

Montalvao P, Mangueira I, Alves G, Cordeiro J, Costa M, Ravanini G Rev Col Bras Cir. 2025; 51():e20243685.

PMID: 39841720 PMC: 11702972. DOI: 10.1590/0100-6991e-20243685-en.


Genetic landscape of Romanian PPGLs.

Lider-Burciulescu S, Gheorghiu M, Braha E, Stanescu L, Patocs A, Badiu C J Cell Mol Med. 2024; 28(23):e70204.

PMID: 39673085 PMC: 11645294. DOI: 10.1111/jcmm.70204.


Impact of Female Sex and Mild Cortisol Secretion on Coagulation Profile in Adrenal Incidentalomas.

Bonaventura I, Minnetti M, Ferrari D, Hasenmajer V, Tomaselli A, De Alcubierre D J Endocr Soc. 2024; 9(1):bvae215.

PMID: 39669652 PMC: 11635453. DOI: 10.1210/jendso/bvae215.


Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms.

Jabczyk M, Nowak J, Mielcarska S, Hudzik B, Wolkowska-Pokrywa K, Swietochowska E Med Sci Monit. 2024; 30:e945899.

PMID: 39600070 PMC: 11610524. DOI: 10.12659/MSM.945899.


The Influence of Remnant Cholesterol on Cardiovascular Risk and Mortality in Patients with Non-Functional Adrenal Incidentalomas and Mild Autonomous Cortisol Secretion: A Retrospective Cohort Study.

Sebastian-Valles F, Fernandez-Moreno M, Garcia-Sanz I, Pascual Gomez N, Navas-Moreno V, Sampedro-Nunez M J Clin Med. 2024; 13(19).

PMID: 39408007 PMC: 11477347. DOI: 10.3390/jcm13195947.